Utah Medical Products Inc
Utah Medical lost its two largest customers but still earns a 31.0% operating margin and holds net cash worth 29.5% of its market value, with no debt.
- Price (13 Nov 26)
- $71.97
- Price target (12m)
- $106.60
- Scenario value*
- $100.51
- Bear/Base/Bull
- 62.59/106.61/126.24
- Market cap
- $205.1M
- Enterprise value
- $144.6M
- Free float
- 92.0% of S/O
- Avg daily vol, 3m
- 33k / $2.3M
- Short interest
- 5.8% float, -0.02pt since 30 Sep
- Institutional own.
- 81.7%
- Largest holder
- Brandes Investment Partners, LP, 16.7%
- Insider and board
- 8.0%
*Probability-weighted, 25/50/25, over 12 months. Price target is the base case, rounded to the nearest ten cents.
The thesis
- The customers behind the sales decline are already gone. Sales for the nine months to 30 September 2026 were $25.9M, down 12.2% from a year earlier. The two lost customers, PendoTECH and a China distributor of blood pressure kits, were 6.4% of FY2025 sales and bought nothing in 2026. So the comparison eases from here.
- Margins have held while sales fell. Nine-month gross margin was 57.5% and operating margin was 31.0%. Q3 gross margin slipped to 56.1% from 57.1% because the plant kept its staffing on lower shipments. The end of Femcare intangible amortization in Q1 2026 lifts operating income without changing cash.
- The balance sheet has no debt and net cash worth almost a third of the market value. Cash and investments were $85.2M at 30 September 2026, before the October tender offer. Pro forma cash is $60.5M, or $21.23 a share against a close of $71.97. Net cash is 29.5% of the $205.1M market capitalisation.
- The stock trades at a discount to every peer on the same measure. Enterprise value is $144.6M, or 11.7x operating income plus D&A for the twelve months to 30 September 2026, against a peer median of 18.4x. We apply that median to FY2027E and reach a price target of $106.60, which is 48.1% above the close.
The full report
6 pages, 513 KB, free with the LALC newsletter.
Leave a comment